| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cross Cancer Institute, Edmonton, Alberta, Canada, T6G 1Z2 [A. J. F., C. J. K., B. M. G., J. S., D. H.], and Department of Radiology and Diagnostic Imaging [A. J. F., C. J. K.], University of Alberta, Edmonton, Alberta, Canada
Misonidazole, a 2-nitroimidazole, has been shown to form metabolically induced adducts to cellular molecules at a very high rate in the absence of oxygen, and this rate decreases substantially as the oxygen concentration increases. Thus, it has considerable potential as a marker for hypoxic, radiation resistant cells in tumors. The dependence of the rate of adduct formation (binding) on oxygen concentration was studied for EMT6/Ed, Walker 256, and Dunning R3327-AT rodent tumors and for two human colon carcinomas, a human melanoma, and a human breast carcinoma. Fragments of these tumors were incubated with [14C]- or [3H]misonidazole in vitro at several oxygen concentrations and the quantity of misonidazole bound was determined from autoradiographs as a function of distance from the surfaces of the fragments. The Km of binding inhibition (oxygen concentration for half-maximal binding) for the tumors varied by a factor of 10. The range was centered on the range of values reported for the Km of cellular radioresistance (oxygen concentration for half-maximal radioresistance). The patterns of binding at depth within the tumor fragments indicated that gradients of cellular waste products and nutrients other than oxygen had minimal effects on binding. All tumors were capable of metabolizing oxygen to levels sufficiently low to yield the maximal binding rate, but the distance of penetration of oxygen varied, indicating a range of at least 4 in rates of oxygen consumption. The ratio of misonidazole bound by stromal tissue versus tumor cells ranged from 0.9 for a colon tumor to 0.3 for a breast tumor. These properties of misonidazole binding indicate that it should be a good marker for radiobiological hypoxia in tumors, providing adequate controls can be performed.
1 Supported by National Cancer Institute of Canada research grants to A. J. F. and C. J. K. and by the Alberta Cancer Board.
2 To whom requests for reprints should be addressed.
Received 11/26/84. Revised 1/27/85. Revised 7/ 8/87. Accepted 7/17/87.
This article has been cited by other articles:
![]() |
M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Evans, S. Hahn, D. R. Pook, W. T. Jenkins, A. A. Chalian, P. Zhang, C. Stevens, R. Weber, G. Weinstein, I. Benjamin, et al. Detection of Hypoxia in Human Squamous Cell Carcinoma by EF5 Binding Cancer Res., April 1, 2000; 60(7): 2018 - 2024. [Abstract] [Full Text] |
||||
![]() |
G. J. Cerniglia, D. F. Wilson, M. Pawlowski, S. Vinogradov, and J. Biaglow Intravascular oxygen distribution in subcutaneous 9L tumors and radiation sensitivity J Appl Physiol, June 1, 1997; 82(6): 1939 - 1945. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |